Analyst Rating Update on Orexigen Therapeutics (OREX)

Orexigen Therapeutics (NASDAQ:OREX) has an average broker rating of 3.2, which is interpreted as a Hold, as rated by 5 equity analysts. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell. 1 considers that the stock is a Sell.

Orexigen Therapeutics (NASDAQ:OREX) : Average target price received by Orexigen Therapeutics (NASDAQ:OREX) is $1.03 with an expected standard deviation of $0.69. The most aggressive target on the stock is $2, whereas the most downbeat target is $1. 4 financial analysts are currently covering the stock.

Company shares have received an average consensus rating of Hold for the current week

Orexigen Therapeutics (NASDAQ:OREX): stock turned positive on Tuesday. Though the stock opened at $0.43, the bulls momentum made the stock top out at $0.456 level for the day. The stock recorded a low of $0.4251 and closed the trading day at $0.4301, in the green by 4.83%. The total traded volume for the day was 1,474,979. The stock had closed at $0.4103 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Commercial Officer) of Orexigen Therapeutics, Inc., Booth Mark D had sold 50,000 shares worth of $284,000 in a transaction dated February 26, 2015. In this transaction, 50,000 shares were sold at $5.68 per share.

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Companys product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Companys product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.